Alector reports $124.6 million net income for Q3 2026
Revenue rose to $162.9 million on GSK deferred revenue recognition; it licensed AL050 to Genentech for $100 million upfront and raised $75 million.
See the latest news and media coverage for Alector. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing therapies for neurodegenerative diseases
alector.comLast updated
In short: Alector reported $124.6 million in Q3 net income, licensed AL050 to Genentech, and raised $75 million.
Revenue rose to $162.9 million on GSK deferred revenue recognition; it licensed AL050 to Genentech for $100 million upfront and raised $75 million.
The company entered an underwriting agreement with Morgan Stanley and BTIG on October 15, 2026 to raise approximately $75.03 million in gross proceeds.
The deal includes up to $1.17 billion in milestones and royalties, extending Alector's cash runway into 2029.
Cash reserves stand at $172.8 million, extending runway through 2027. The company also highlighted progress in its ABC platform programs including AL137 for Alzheimer's disease.
Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled...
Alector Inc. is getting $100 million up front, with the potential of up to $1.17 billion in milestones, in a deal with Roche AG's Genentech...
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead...
Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.
Track Alector and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Alector and other trending companies.